The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Your Guide to Hip Replacement Surgery . What Is a Hip Replacement? The hip is one of the largest joints in the body and is shaped as a ball and socke ...

Intra-articular synovial hemangioma of the knee is a relatively rare benign tumor that if left undiagnosed and treated may be ...

to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of ...

The US Food and Drug Administration (FDA) has approved Celltrion’s biosimilars referencing Amgen’s bone disease therapy ...

On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...

Overview: Initial test, a single-arm, open-label 1st-in-human proof-of-concept study in adults with distal radius fractures.

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

Think Surgical today announced the first successful use of Waldemar Link's LinkSymphoKnee using the TMINI Miniature Robotic ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).